Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Change in Receivables (2016 - 2025)

Mimedx's Change in Receivables history spans 14 years, with the latest figure at $887000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables fell 60.63% year-over-year to $887000.0; the TTM value through Dec 2025 reached $26.4 million, up 934.25%, while the annual FY2025 figure was $26.4 million, 934.25% up from the prior year.
  • Change in Receivables for Q4 2025 was $887000.0 at Mimedx, down from $11.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $11.0 million in Q3 2025 and bottomed at -$4.0 million in Q2 2024.
  • The 5-year median for Change in Receivables is $2.3 million (2022), against an average of $2.9 million.
  • The largest annual shift saw Change in Receivables plummeted 89200.0% in 2022 before it surged 1055.72% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $9.5 million in 2021, then tumbled by 72.21% to $2.6 million in 2022, then soared by 111.13% to $5.6 million in 2023, then plummeted by 59.61% to $2.3 million in 2024, then tumbled by 60.63% to $887000.0 in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Change in Receivables are $887000.0 (Q4 2025), $11.0 million (Q3 2025), and $7.3 million (Q2 2025).